EA200300594A1 - Усилители гамк при лечении заболеваний, связанных со сниженной активностью нейростероидов - Google Patents
Усилители гамк при лечении заболеваний, связанных со сниженной активностью нейростероидовInfo
- Publication number
- EA200300594A1 EA200300594A1 EA200300594A EA200300594A EA200300594A1 EA 200300594 A1 EA200300594 A1 EA 200300594A1 EA 200300594 A EA200300594 A EA 200300594A EA 200300594 A EA200300594 A EA 200300594A EA 200300594 A1 EA200300594 A1 EA 200300594A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gaba
- treatment
- amplifiers
- diseases associated
- activity
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 title abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 abstract 1
- 102000005915 GABA Receptors Human genes 0.000 abstract 1
- 108010005551 GABA Receptors Proteins 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000003371 gabaergic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Изобретение представляет применение нестероидного соединения, которое действует на рецептор ГАМК, для лечения расстройств, связанных со сниженной активностью нейростероидов. Нестероидные соединения могут представлять собой агонисты ГАМК, ингибиторы захвата ГАМК или усилители ГАМК-ергической активности.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001743 | 2000-11-20 | ||
PCT/DK2001/000773 WO2002040009A1 (en) | 2000-11-20 | 2001-11-20 | Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200300594A1 true EA200300594A1 (ru) | 2003-10-30 |
EA007287B1 EA007287B1 (ru) | 2006-08-25 |
Family
ID=8159857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200300594A EA007287B1 (ru) | 2000-11-20 | 2001-11-20 | Усилители гамк при лечении заболеваний, связанных со сниженной активностью нейростероидов |
Country Status (34)
Country | Link |
---|---|
US (2) | US20040024038A1 (ru) |
EP (1) | EP1337247B1 (ru) |
JP (1) | JP4152186B2 (ru) |
KR (1) | KR100865651B1 (ru) |
CN (1) | CN1318027C (ru) |
AR (1) | AR031473A1 (ru) |
AT (1) | ATE336242T1 (ru) |
AU (2) | AU2002223514B2 (ru) |
BG (1) | BG107909A (ru) |
BR (1) | BR0115668A (ru) |
CA (1) | CA2429220C (ru) |
CY (1) | CY1106209T1 (ru) |
CZ (1) | CZ20031383A3 (ru) |
DE (1) | DE60122368T2 (ru) |
DK (1) | DK1337247T3 (ru) |
EA (1) | EA007287B1 (ru) |
ES (1) | ES2266308T3 (ru) |
HK (1) | HK1075010A1 (ru) |
HR (1) | HRP20030404A2 (ru) |
HU (1) | HUP0400505A3 (ru) |
IL (1) | IL155587A0 (ru) |
IS (1) | IS2427B (ru) |
ME (1) | MEP6408A (ru) |
MX (1) | MXPA03004349A (ru) |
NO (1) | NO20032271L (ru) |
NZ (1) | NZ525520A (ru) |
PL (1) | PL361051A1 (ru) |
PT (1) | PT1337247E (ru) |
SI (1) | SI1337247T1 (ru) |
SK (1) | SK7682003A3 (ru) |
UA (1) | UA77403C2 (ru) |
WO (1) | WO2002040009A1 (ru) |
YU (1) | YU39003A (ru) |
ZA (1) | ZA200303289B (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
US11597726B2 (en) | 2020-05-20 | 2023-03-07 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
DE50214447D1 (de) * | 2001-11-26 | 2010-07-01 | Finzelberg Gmbh & Co Kg | Ingwer-extraktzubereitung |
MXPA05013016A (es) * | 2003-06-25 | 2006-03-02 | Lundbeck & Co As H | Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos. |
GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
WO2006053556A1 (en) * | 2004-06-29 | 2006-05-26 | H. Lundbeck A/S | Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis |
WO2006012563A2 (en) * | 2004-07-23 | 2006-02-02 | The Regents Of The University Of California | Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle |
GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
US20070122507A1 (en) * | 2005-05-26 | 2007-05-31 | Palu Afa K | Histone deacetylase and tumor necrosis factor converting enzyme inhibition |
US8078688B2 (en) * | 2006-12-29 | 2011-12-13 | Prodea Systems, Inc. | File sharing through multi-services gateway device at user premises |
WO2008141112A1 (en) * | 2007-05-09 | 2008-11-20 | Cenerx Biopharma, Inc. | Methods of treating rett syndrome |
CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
CN103547240B (zh) * | 2011-06-16 | 2016-03-30 | 索雷斯生命科学公司 | 用于人类自主神经系统的平衡和维持健康的系统和方法 |
RU2496496C1 (ru) * | 2012-10-04 | 2013-10-27 | Исаак Григорьевич Гитлин | Фармацевтическая композиция, обладающая гамк-ергической активностью |
KR20230050474A (ko) * | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
KR102049522B1 (ko) * | 2018-06-05 | 2019-11-27 | 충남대학교산학협력단 | Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물 |
KR102049526B1 (ko) * | 2018-06-05 | 2019-11-27 | 충남대학교산학협력단 | Gaba를 유효성분으로 하는 항결핵 약학 조성물 |
EP3833351A4 (en) | 2018-09-20 | 2021-10-13 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS |
CN113423399A (zh) | 2018-12-17 | 2021-09-21 | 奥维德医疗公司 | 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途 |
AU2020259406A1 (en) | 2019-04-17 | 2021-11-04 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
IL293924A (en) | 2019-12-18 | 2022-08-01 | Ovid Therapeutics Inc | Goxadol for medical treatment in 1p36 deletion syndrome |
CN114404437A (zh) * | 2022-03-15 | 2022-04-29 | 山东中医药大学 | 没食子酰芍药苷在制备gabaa受体抑制剂中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4362731A (en) * | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US5120723A (en) * | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
AU2657292A (en) * | 1991-09-13 | 1993-04-27 | Cocensys, Inc. | Novel gabaa receptor with steroid binding sites |
US5206415A (en) * | 1991-12-20 | 1993-04-27 | Washington University | Tricyclic steroid analogs |
CZ300694A3 (en) * | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
CZ292881B6 (cs) * | 1994-11-23 | 2003-12-17 | Euro-Celtique S.A. | Androstanová a pregnanová řada pro allosterickou modulaci GABA receptoru |
US5776959A (en) * | 1995-06-05 | 1998-07-07 | Washington University | Anticonvulsant and anxiolytic lactam and thiolactam derivatives |
DE69634039T2 (de) * | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
IT1290003B1 (it) * | 1997-03-03 | 1998-10-19 | Angelini Ricerche Spa | Uso di pivagabina per preparare composizioni farmaceutiche |
GB9801208D0 (en) * | 1998-01-21 | 1998-03-18 | Merck Sharp & Dohme | Therapeutic agents |
AU758808B2 (en) * | 1998-07-22 | 2003-03-27 | N.V. Organon | Alpha-amino acid phenyl ester derivatives |
WO2001042190A1 (en) * | 1999-12-08 | 2001-06-14 | Warner-Lambert Company | Method for the stereoselective synthesis of cyclic amino acids |
-
2001
- 2001-11-16 AR ARP010105378A patent/AR031473A1/es unknown
- 2001-11-20 DK DK01996378T patent/DK1337247T3/da active
- 2001-11-20 YU YU39003A patent/YU39003A/sh unknown
- 2001-11-20 PT PT01996378T patent/PT1337247E/pt unknown
- 2001-11-20 AU AU2002223514A patent/AU2002223514B2/en not_active Ceased
- 2001-11-20 UA UA2003054188A patent/UA77403C2/uk unknown
- 2001-11-20 CZ CZ20031383A patent/CZ20031383A3/cs unknown
- 2001-11-20 CA CA002429220A patent/CA2429220C/en not_active Expired - Fee Related
- 2001-11-20 SK SK768-2003A patent/SK7682003A3/sk not_active Application Discontinuation
- 2001-11-20 DE DE60122368T patent/DE60122368T2/de not_active Expired - Lifetime
- 2001-11-20 MX MXPA03004349A patent/MXPA03004349A/es active IP Right Grant
- 2001-11-20 WO PCT/DK2001/000773 patent/WO2002040009A1/en active IP Right Grant
- 2001-11-20 BR BR0115668-3A patent/BR0115668A/pt not_active Application Discontinuation
- 2001-11-20 EA EA200300594A patent/EA007287B1/ru not_active IP Right Cessation
- 2001-11-20 EP EP01996378A patent/EP1337247B1/en not_active Expired - Lifetime
- 2001-11-20 SI SI200130619T patent/SI1337247T1/sl unknown
- 2001-11-20 ME MEP-64/08A patent/MEP6408A/xx unknown
- 2001-11-20 AT AT01996378T patent/ATE336242T1/de active
- 2001-11-20 KR KR1020037006754A patent/KR100865651B1/ko not_active IP Right Cessation
- 2001-11-20 HU HU0400505A patent/HUP0400505A3/hu unknown
- 2001-11-20 PL PL36105101A patent/PL361051A1/xx unknown
- 2001-11-20 ES ES01996378T patent/ES2266308T3/es not_active Expired - Lifetime
- 2001-11-20 IL IL15558701A patent/IL155587A0/xx unknown
- 2001-11-20 AU AU2351402A patent/AU2351402A/xx active Pending
- 2001-11-20 NZ NZ525520A patent/NZ525520A/en unknown
- 2001-11-20 JP JP2002542383A patent/JP4152186B2/ja not_active Expired - Fee Related
- 2001-11-20 CN CNB018190936A patent/CN1318027C/zh not_active Expired - Fee Related
-
2003
- 2003-04-29 ZA ZA2003/03289A patent/ZA200303289B/en unknown
- 2003-04-30 IS IS6803A patent/IS2427B/is unknown
- 2003-05-01 US US10/430,704 patent/US20040024038A1/en not_active Abandoned
- 2003-05-20 NO NO20032271A patent/NO20032271L/no not_active Application Discontinuation
- 2003-05-20 HR HR20030404A patent/HRP20030404A2/hr not_active Application Discontinuation
- 2003-06-13 BG BG107909A patent/BG107909A/bg unknown
-
2005
- 2005-08-23 HK HK05107388A patent/HK1075010A1/xx not_active IP Right Cessation
-
2006
- 2006-10-20 CY CY20061101505T patent/CY1106209T1/el unknown
-
2008
- 2008-06-27 US US12/163,883 patent/US20090143435A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
US11597726B2 (en) | 2020-05-20 | 2023-03-07 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300594A1 (ru) | Усилители гамк при лечении заболеваний, связанных со сниженной активностью нейростероидов | |
CY1122522T1 (el) | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος | |
BR0313371A (pt) | Composto, uso de um composto e método de tratamento de doença | |
EA200200208A1 (ru) | Синергитическая композиция | |
UY26970A1 (es) | Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos | |
CY1112605T1 (el) | Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων | |
MX2009001327A (es) | Compuestos de indol. | |
CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
ECSP034519A (es) | Inhibidores de xantina fosfodiesterasa v | |
BRPI0414048A (pt) | conjunto de ìmã permanente | |
BRPI0412684A (pt) | compostos ppar-ativos | |
ECSP055913A (es) | Inhibidores de las polimerasas víricas | |
DE60127537D1 (de) | VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE | |
EA200201252A1 (ru) | Соединения, эффективные в качестве агонистов э2 - адренорецептора и ингибиторов фосфодиэстеразы pde4 | |
MA31821B1 (fr) | Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
CY1109529T1 (el) | 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων | |
MA31707B1 (fr) | Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1 | |
MX2007009032A (es) | Formulacion para inyeccion de butanos catecolicos incluyendo compuestos ndga en animales. | |
RS49795B (sr) | Sredstva sa antidepresivnim dejstvom | |
DK1117403T3 (da) | MGLUR5-antagonister til behandling af smerte og angst | |
ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
TR200003384T2 (tr) | Arginin türevleri kullanılarak oksazolidinon antibakteriyel maddelerin etkisinin arttırılması | |
BR0011801A (pt) | Inibidores de benzamida substituìda para 3c protease de rinovìrus | |
UA99901C2 (en) | Indole compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |